Amarin Corp Plc (AMRN)

[couldbebetter]

TalShu, Outstanding reply to my post. What I found most interesting
is how entrenched Novo Nordisk is in China. Of course, Europe is the
most important market for a potential acquirer. China is an enigma.
However, if an acquirer of AMRN (mainly for what they could do
with Vazkepa in Europe) also had a way to optimize (or should I
say to help Eddingpharm optimize) the uptake of Vascepa in China,
that could be a real bonus. Of course, once China approves Vascepa
for CVD that would be major step forward. If Eddingpharm were to
work with a BP owner of AMRN that could provide greater distribution
& other support (maybe with IP) that could be a win-win. Thanks
again for well thought out and carefully documented comments!